BTIG raised the firm’s price target on Climb Bio (CLYM) to $8 from $7 and keeps a Buy rating on the shares. With a positive dose-response seen with sibeprenlimab in IgAN, the firm believes that CLYM116 is well-positioned to drive even greater efficacy at two to three-times the half life compared to sibeprenlimab in NHPs – nonhuman primate, the analyst tells investors in a research note. The long half life also refuted any speculation that target-mediated drug disposition could impair CLYM116’s PK, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM:
- Climb Bio Unveils Promising Preclinical Data for CLYM116
- Climb Bio announces CLYM116 preclinical data
- Climb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunity
- Climb Bio: Strong Clinical Execution and Promising Pipeline Make It a Compelling Investment Opportunity
- Climb Bio initiated with an Outperform at Baird on budoprutug potential